HDAC inhibitors have been shown to induce cell death by suppressing survivin expression in various cancer cells, including non-small cell lung cancer (NSCLC), renal cell carcinoma and epidermoid carcinoma [18–22]. Here, BIRC5 is linked to non-small cell lung carcinoma.